Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial.

Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J, Sequeira R, Kent CK, Bacchetta M, Goldman C, Salenius JP, Schmieder FA, Pilsudski R.

J Vasc Surg. 2002 May;35(5):930-6.

2.

Genetic immunization of neonates.

Bot A, Bona C.

Microbes Infect. 2002 Apr;4(4):511-20. Review.

PMID:
11932202
3.
4.

Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli.

Yamagami S, Motoki M, Kimura T, Izumi H, Takeda T, Katsuura Y, Matsumoto Y.

J Infect Dis. 2001 Sep 15;184(6):738-42. Epub 2001 Aug 9.

PMID:
11517435
5.

Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies.

Byun Y, Ohmura M, Fujihashi K, Yamamoto S, McGhee JR, Udaka S, Kiyono H, Takeda Y, Kohsaka T, Yuki Y.

Vaccine. 2001 Feb 28;19(15-16):2061-70.

PMID:
11228378
6.

[Protection against influenza by genetically engineered vaccines].

Abe T, Takaku H.

Nihon Rinsho. 2000 Nov;58(11):2313-20. Review. Japanese.

PMID:
11225323
7.

Immunoprophylactic potential of cloned Shiga toxin 2 B subunit.

Marcato P, Mulvey G, Read RJ, Vander Helm K, Nation PN, Armstrong GD.

J Infect Dis. 2001 Feb 1;183(3):435-43. Epub 2000 Dec 27.

PMID:
11133375
8.

Intervention with Shiga toxin (Stx) antibody after infection by Stx-producing Escherichia coli.

Matise I, Cornick NA, Booher SL, Samuel JE, Bosworth BT, Moon HW.

J Infect Dis. 2001 Jan 15;183(2):347-350. Epub 2000 Dec 8.

PMID:
11110647
9.

Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice.

Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, Otten GR, Ulmer JB, Donnelly JJ, Ott G, McDonald DM.

J Immunol. 2000 Sep 1;165(5):2850-8.

10.

Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT.

Eur Urol. 2000 Aug;38(2):208-17.

PMID:
10895014
12.

Shiga toxin-2 induces neutrophilia and neutrophil activation in a murine model of hemolytic uremic syndrome.

Fernández GC, Rubel C, Dran G, Gómez S, Isturiz MA, Palermo MS.

Clin Immunol. 2000 Jun;95(3):227-34.

PMID:
10866130
13.

Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus.

Sedegah M, Weiss W, Sacci JB Jr, Charoenvit Y, Hedstrom R, Gowda K, Majam VF, Tine J, Kumar S, Hobart P, Hoffman SL.

J Immunol. 2000 Jun 1;164(11):5905-12.

14.

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines.

Boyer JD, Cohen AD, Vogt S, Schumann K, Nath B, Ahn L, Lacy K, Bagarazzi ML, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, MacGregor RR, Weiner DB.

J Infect Dis. 2000 Feb;181(2):476-83.

PMID:
10669329
15.

Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality.

Palermo M, Alves-Rosa F, Rubel C, Fernández GC, Fernández-Alonso G, Alberto F, Rivas M, Isturiz M.

Clin Exp Immunol. 2000 Jan;119(1):77-83.

16.

DNA and RNA-based vaccines: principles, progress and prospects.

Leitner WW, Ying H, Restifo NP.

Vaccine. 1999 Dec 10;18(9-10):765-77. Review.

17.

Induction of immune responses to bovine herpesvirus type 1 gD in passively immune mice after immunization with a DNA-based vaccine.

Lewis PJ, van Drunen Littel-Van Den Hurk, Babiuk LA.

J Gen Virol. 1999 Nov;80 ( Pt 11):2829-37.

PMID:
10580044
18.

Prevention of neonatal tolerance by a plasmid encoding granulocyte-macrophage colony stimulating factor.

Ishii KJ, Weiss WR, Klinman DM.

Vaccine. 1999 Nov 12;18(7-8):703-10.

PMID:
10547430
19.
20.

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.

MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB.

J Infect Dis. 1998 Jul;178(1):92-100.

PMID:
9652427

Supplemental Content

Support Center